<DOC>
	<DOC>NCT00239577</DOC>
	<brief_summary>This descriptive study will evaluate the safety and immunogenicity of 5 different formulations of the WRAIR dengue vaccine compared to a placebo.</brief_summary>
	<brief_title>A Trial of a Walter Reed Army Institute of Research (WRAIR) Live Attenuated Virus Tetravalent Dengue Vaccine in Healthy US Adults</brief_title>
	<detailed_description>Subjects will be randomized into one of 6 groups. One group will receive a placebo vaccine and the others will receive one of 5 different dengue vaccine formations. Each subject will receive two doses six months apart. Study subjects who elect to participate in a mosquito transmissibility component of the study will undergo mosquito feedings during each of the two assigned follow-up visits after vaccine dose 1. All subjects will have 11 venipunctures during 11 visits (i.e., screening plus 10 study visits) over a period of nine months.</detailed_description>
	<mesh_term>Dengue</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion: Healthy male or female adult 1845 years at the time of vaccination Free of obvious health problems as established by medical history and physical examination before entering into the study Written informed consent obtained from the subject Able to read the Subject Information Sheet and Consent Form Subjects who the investigator believes can and will comply with the requirements of the protocol Females must be of nonchildbearing potential, or, if of childbearing potential, she must be abstinent or have used adequate contraceptive precautions as defined in the protocol for 30 days prior to vaccination, have a negative pregnancy test within 48 hours prior to vaccination and must agree to continue such precautions for 60 days after completion of the vaccination series Exclusion: History of: recurrent migraine headache any neurological or behavioral disorder or seizures drug abuse or alcohol consumption (more than 2 drinks per day) allergic disease/reaction likely to be exacerbated by vaccine urticaria related to mosquito bites requiring medical attention Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic, renal, hematologic or endocrine functional defect Any confirmed or suspected immunosuppressive or immunodeficient condition; Seropositive for HBsAg, antiHCV or antiHIV Acute disease at the time of enrollment Chronic hepatomegaly or splenomegaly Use of any investigational or nonregistered drug or vaccine within 30 days preceding study or planned use Planned administration of a vaccine not foreseen by the study protocol 30 days Â±each vaccine dose Planned move during study Chronic administration (defined as more than 14 days) of immunosuppressants or other immunemodifying drugs or administration of immunoglobulins and/or blood products, within 90 days preceding the first dose or planned administration during the study period Any chronic systemic drug therapy to be continued during the study period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>Dengue infection</keyword>
</DOC>